We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+1.11%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.2B
AUM Growth
-$1.07B
Cap. Flow
-$834M
Cap. Flow %
-19.85%
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$203M
2
GILD icon
Gilead Sciences
GILD
+$156M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$146M
4
AMGN icon
Amgen
AMGN
+$98.7M
5
VRDN icon
Viridian Therapeutics
VRDN
+$70.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$350M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$235M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$225M
4
RNAM
Avidity Biosciences
RNAM
+$190M
5
FOLD
Amicus Therapeutics
FOLD
+$153M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Energy 0.07%
3 Technology 0.06%
4 Financials 0.03%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$123B
$304M 7.25%
681,908
+788
+0.1% +$367K
ARGX icon
2
argenx
ARGX
$53.7B
$229M 5.44%
313,000
-148,854
-32% -$116M
REGN icon
3
Regeneron Pharmaceuticals
REGN
$71.2B
$215M 5.12%
278,674
+264,746
+1,901% +$203M
SRRK icon
4
Scholar Rock
SRRK
$6.2B
$176M 4.19%
3,584,573
-472,019
-12% -$21.2M
GILD icon
5
Gilead Sciences
GILD
$169B
$163M 3.88%
1,169,879
+1,117,127
+2,118% +$156M
RVMD icon
6
Revolution Medicines
RVMD
$38.1B
$150M 3.57%
1,544,456
-3,461,263
-69% -$350M
IONS icon
7
Ionis Pharmaceuticals
IONS
$9.03B
$137M 3.25%
1,818,665
-2,983,534
-62% -$235M
ISRG icon
8
Intuitive Surgical
ISRG
$142B
$132M 3.14%
286,654
-35,374
-11% -$17.9M
VRDN icon
9
Viridian Therapeutics
VRDN
$1.99B
$132M 3.13%
6,726,144
+2,367,617
+54% +$70.3M
KRYS icon
10
Krystal Biotech
KRYS
$10.1B
$124M 2.96%
481,785
+71,462
+17% +$19M
CRNX icon
11
Crinetics Pharmaceuticals
CRNX
$8.88B
$119M 2.84%
3,280,000
+3,275,960
+81,088% +$146M
ABT icon
12
Abbott
ABT
$172B
$118M 2.81%
1,151,635
-165,280
-13% -$18.7M
NUVL
13
DELISTED
Nuvalent
NUVL
$108M 2.57%
1,053,268
+15,800
+2% +$1.61M
AMGN icon
14
Amgen
AMGN
$201B
$104M 2.47%
295,358
+276,869
+1,497% +$98.7M
BSX icon
15
Boston Scientific
BSX
$66.3B
$92M 2.19%
1,466,894
-92,712
-6% -$7.42M
ELVN icon
16
Enliven Therapeutics
ELVN
$3.63B
$91M 2.17%
+2,320,867
New +$64.3M
IMCR icon
17
Immunocore
IMCR
$1.75B
$84.3M 2.01%
2,796,803
– –
MDT icon
18
Medtronic
MDT
$107B
$83M 1.97%
957,329
+190,737
+25% +$18.3M
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$37.8B
$77.6M 1.85%
234,543
-211,360
-47% -$71.9M
RLAY icon
20
Relay Therapeutics
RLAY
$4.22B
$77.6M 1.85%
7,795,242
-550,122
-7% -$4.92M
SYK icon
21
Stryker
SYK
$127B
$71.4M 1.7%
217,237
-143,340
-40% -$51.5M
PCVX icon
22
Vaxcyte
PCVX
$8.09B
$69.2M 1.65%
+1,190,697
New +$64.6M
VERA icon
23
Vera Therapeutics
VERA
$2.81B
$68.8M 1.64%
1,710,771
+12,619
+0.7% +$544K
EW icon
24
Edwards Lifesciences
EW
$50.6B
$67.2M 1.6%
839,451
-203,645
-20% -$16.8M
DMRA
25
Damora Therapeutics
DMRA
$1.86B
$59.5M 1.42%
+2,298,000
New +$59.1M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2026 Portfolio in Review

As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.

Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.

  • Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
  • Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
  • Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
  • Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
  • Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
  • Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
  • Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.